Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Ming-Ming Zhao

2 papers in the library · 19 citations · publishing 2024-2025

Papers

Transforming growth factor-β1 mediates the beneficial effects of arketamine on demyelination and remyelination in the brains of cuprizone-treated mice.

European Journal of Pharmacology December 15, 2024 Ming-Ming Zhao, Ting-Ting Zhu, Dan Xu et al. 14 citations

Arketamine, the (R)-enantiomer of ketamine, reduces damage to the myelin sheath and promotes its repair in the brains of mice treated with cuprizone, a chemical that induces demyelination. The beneficial effects occur through a mechanism dependent on transforming growth factor β1 (TGF-β1). Blocking the TGF-β1 receptor with RepSox prevented arketamine's protective effects. Directly administering TGF-β1 intranasally also reduced demyelination and enhanced remyelination in the corpus callosum. These findings suggest that arketamine's effects on myelin repair rely on TGF-β1 signaling, pointing to potential therapeutic targets for demyelinating diseases like multiple sclerosis.

DOI: 10.1016/j.ejphar.2024.177096 (opens in new tab) Full text (opens in new tab) Arketamine Cuprizone Demyelination Remyelination +6

Arketamine alleviates cognitive impairments and demyelination in mice with postoperative cognitive dysfunction via TGF-β1 activation.

Progress in neuro-psychopharmacology & biological psychiatry January 10, 2025 Ting-Ting Zhu, Ming-Ming Zhao, Dan Xu et al. 5 citations

Postoperative cognitive dysfunction (POCD) involves declines in memory, attention, and executive abilities after surgery, with no effective drugs available. In a mouse model of POCD, a single injection of arketamine (10 mg/kg) improved cognitive function and reduced demyelination in the corpus callosum. Blocking TGF-β receptor 1 with RepSox (10 mg/kg) prevented these benefits, while intranasal TGF-β1 (3.0 μg/kg) alone alleviated cognitive impairments and demyelination. The findings indicate arketamine acts through a TGF-β1-dependent mechanism, suggesting it as a potential treatment for POCD.

DOI: 10.1016/j.pnpbp.2024.111228 (opens in new tab) Full text (opens in new tab) Arketamine Demyelination Postoperative cognitive dysfunction Surgery +6